Dacomitinib as a First‐Line Therapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study

ABSTRACT Background Real‐world evidence regarding the use of dacomitinib as a first‐line therapy for advanced non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This multicenter, retrospective cohort study aimed to evaluate the clinical outcome...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ping‐Chih Hsu, How‐Wen Ko, Li‐Chung Chiu, Shih‐Hao Huang, Chung‐Shu Lee, Yu‐Ching Lin, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Chin‐Chou Wang, Cheng‐Ta Yang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2026-03-01
coleção:	Cancer Medicine
Assuntos:	common EGFR mutation dacomitinib epidermal growth factor receptor mutation non‐small cell lung cancer (NSCLC) tyrosine kinase inhibitor
Acesso em linha:	https://doi.org/10.1002/cam4.71659
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!